Dimethyl Sulfoxide
Apexbio Technology LLC BMS-777607 1025720-94-8 10mM (in 1mL DMSO)
BMS-777607 (CAS 1025720-94-8) is an orally bioavailable ATP-competitive inhibitor targeting MET kinase and related receptor tyrosine kinases It selectively inhibits members of the MET family including RON MET Tyro-3 and Axl with IC50 values of 1 8 nmol/L 3 9 nmol/L 4 3 nmol/L and 1 1 nmol/L respectively At higher doses it also inhibits additional tyrosine kinases such as Mer Flt-3 Aurora B Lck and VEGFR2 BMS-777607 has been shown to suppress c-Met autophosphorylation (IC50 20 nmol/L) thereby impairing tumor xenograft growth and metastatic phenotypes supporting its utility in oncological research models exploring MET-driven tumorigenesis and cancer progression
Apexbio Technology LLC PCI-24781 (CRA-024781) 783355-60-2 10mM (in 1mL DMSO)
PCI-24781 (CRA-024781 CAS 783355-60-2) is a histone deacetylase (HDAC) inhibitor targeting HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 and HDAC10 with reported Ki values of 7 19 8 2 17 280 and 24 nM respectively HDAC enzymes catalyze the removal of acetyl groups from lysine residues on histone proteins thereby regulating chromatin structure and gene expression PCI-24781 induces dose-dependent hyperacetylation of histones and tubulin in human cancer cells (HCT116 DLD-1) leading to apoptosis via p21 upregulation PARP cleavage and H2AX accumulation PCI-24781 demonstrates antitumor activity against multiple tumor cell lines and in xenograft models highlighting its utility for oncology research
Apexbio Technology LLC BML-210(CAY10433) 537034-17-6 10mM (in 1mL DMSO)
BML-210 (CAY10433 CAS 537034-17-6) is a small molecule inhibitor targeting histone deacetylases (HDACs) enzymes responsible for removing acetyl groups from lysine residues on histone proteins leading to chromatin compaction and transcriptional repression BML-210 demonstrates HDAC inhibitory activity with an IC50 of 87 M In cellular assays this compound increases FXN mRNA expression and histone H4 acetylation induces G1 cell cycle arrest and apoptosis and enhances erythroid and granulocytic differentiation in human leukemia cell lines (K562 HL-60) BML-210 is utilized in research investigating epigenetic modulation leukemia biology and gene regulation mechanisms
Apexbio Technology LLC ML347 1062368-49-3 10mM (in 1mL DMSO)
ML347 (CAS 1062368-49-3) is a potent and selective inhibitor of bone morphogenetic protein (BMP) type I receptors specifically targeting ALK2 Mechanistically ML347 selectively inhibits ALK2 kinase activity with an IC50 of 32 nM while also inhibiting ALK1 with a comparable IC50 of 46 nM Notably ML347 displays approximately 300-fold selectivity for ALK2 over ALK3 and lacks inhibitory activity against closely related kinases such as ALK6 and KDR In the BMP4-induced C2C12BRA cell-based assay ML347 exhibits inhibitory activity with an IC50 of 152 nM As a selective ALK2 inhibitor ML347 serves as a valuable probe in BMP pathway research
Apexbio Technology LLC Influenza Hemagglutinin (HA) Peptide 92000-76-5 10mM (in 1mL DMSO)
Influenza hemagglutinin (HA) peptide (sequence YPYDVPDYA) is commonly utilized in biomedical studies as an epitope tag for protein detection and isolation Derived from the influenza virus hemagglutinin protein HA mediates viral entry into host cells through initial receptor binding (via HA1 subunit) and subsequent membrane fusion (via HA2 subunit) Under acidic intracellular conditions HA undergoes conformational changes enabling membrane destabilization and viral fusion Synthetic HA-derived peptides can mimic this fusogenic mechanism enhancing gene transfer efficiency in vitro through promoting cellular uptake of transfection complexes in various cultured cell lines including K562 HeLa and BNL CL 2 hepatocyte cells Typically employed within transferrin-polylysine-DNA based delivery systems these HA peptides facilitate membrane disruption increasing complex internalization reported IC50 values vary depending on specific cellular systems and experimental conditions
Apexbio Technology LLC CEP-18770 847499-27-8 10mM (in 1mL DMSO)
CEP-18770 (CAS 847499-27-8) is a reversible boronic acid-based inhibitor of proteasome chymotrypsin-like activity It specifically targets the proteasome s P2 threonine protease subunit reducing NF- B signaling and the expression of downstream effectors With a reported IC50 of 3 8 nM CEP-18770 induces apoptosis in multiple myeloma cell lines and inhibits osteoclastogenesis and angiogenesis via suppression of RANKL signaling Research supports its potential use in oncology particularly for multiple myeloma showing selective cytotoxicity sparing normal epithelial and bone marrow-derived cells
Apexbio Technology LLC Mocetinostat (MGCD0103, MG0103) 726169-73-9 10mM (in 1mL DMSO)
Mocetinostat (MGCD0103 MG0103 CAS 726169-73-9) is an isotype-selective inhibitor of human histone deacetylases (HDACs) It selectively targets class I HDAC enzymes (HDAC1 HDAC2 HDAC3) and class IV HDAC11 without affecting class II HDACs Mocetinostat inhibits these isoforms with IC50 values of 0 15 mol/L (HDAC1) 0 29 mol/L (HDAC2) 1 66 mol/L (HDAC3) and 0 59 mol/L (HDAC11) resulting in histone hyperacetylation cell cycle arrest and apoptosis in various cancer cell lines It serves as a research tool for studying epigenetic regulation and as a candidate compound for anticancer drug development
Apexbio Technology LLC UNC 0642(Synonyms: UNC0642, UNC-0642, G9a/GLP inhibitor UNC0642, UNC0642 inhibitor, G9a inhibitor UNC0642), 10mM (in 1mL DMSO), CAS: 1481677-78-4.
UNC 0642 (CAS 1481677-78-4) is a selective small-molecule inhibitor targeting lysine methyltransferases G9a and GLP These enzymes catalyze dimethylation of lysine 9 on histone H3 (H3K9) impacting chromatin organization and transcriptional regulation UNC 0642 inhibits G9a enzymatic activity with potent nanomolar affinity (IC50 2 5 nM) in cellular assays It is employed in epigenetic studies investigating G9a/GLP-mediated gene silencing and holds relevance in cancer biology neuroscience and stem cell research
Apexbio Technology LLC Teriflunomide 108605-62-5 10mM (in 1mL DMSO)
Teriflunomide (CAS 108605-62-5) the active metabolite of the antirheumatic agent Leflunomide acts primarily by selectively inhibiting dihydroorotate dehydrogenase (DHODH) a mitochondrial enzyme critical for pyrimidine nucleotide synthesis By restricting pyrimidine production teriflunomide exerts antiproliferative effects on activated lymphocytes resulting in immunosuppressive and anti-inflammatory activity Due to these properties teriflunomide is extensively studied as an oral therapeutic candidate in multiple sclerosis research addressing autoimmune-mediated disorders
Apexbio Technology LLC CUDC-101 1012054-59-9 10mM (in 1mL DMSO)
CUDC-101 (CAS 1012054-59-9) is a multitargeted small molecule inhibitor that concurrently targets epidermal growth factor receptor (EGFR) HER2 and class I and II histone deacetylases (HDACs) By inhibiting EGFR and HER2 kinases directly and simultaneously blocking HDAC activity CUDC-101 downregulates multiple oncogenic signaling pathways including those mediated by Akt HER3 and MET Preclinical assessments demonstrate that CUDC-101 inhibits growth of diverse tumor cell lines and xenograft models notably including those resistant to EGFR-targeted agents such as lapatinib and erlotinib These characteristics render CUDC-101 valuable for oncology research and drug resistance studies
Apexbio Technology LLC Rucaparib (AG-014699,PF-01367338) 459868-92-9 10mM (in 1mL DMSO)
Rucaparib (AG-014699 PF-01367338 CAS 459868-92-9) is a small molecule inhibitor targeting poly(ADP-ribose) polymerase (PARP) a nuclear enzyme activated by DNA damage and central to the base excision repair pathway By blocking PARP activity rucaparib impairs DNA repair especially in cells with pre-existing DNA repair deficiencies such as those induced by genotoxic stress In prostate cancer research rucaparib induces radiosensitization notably in PTEN-deficient cells expressing ETS fusion proteins through inhibition of non-homologous end joining (NHEJ) It is thus relevant in studies investigating DNA damage response pathways cancer biology and therapeutic radiosensitization strategies
Apexbio Technology LLC Posaconazole 171228-49-2 10mM (in 1mL DMSO)
Posaconazole a triazole antifungal derivative of itraconazole acts by inhibition of sterol 14 -demethylase involved in fungal ergosterol biosynthesis It binds directly to the enzyme s heme cofactor blocking conversion of lanosterol into downstream sterol intermediates disrupting fungal membrane integrity and cellular function Posaconazole shows inhibitory activity in vitro against Candida albicans strains (IC50 0 007 0 3 g/ml) and Aspergillus species including A fumigatus and A flavus (IC50 0 03 g/ml) It is commonly utilized in biomedical research investigating fungal biology and drug resistance mechanisms
Apexbio Technology LLC VX-809 936727-05-8 10mM (in 1mL DMSO)
VX-809 (CAS 936727-05-8) is a small molecule CFTR corrector that partially restores the functional expression of F508del-CFTR the most common mutation associated with cystic fibrosis (CF) VX-809 stabilizes the misfolded CFTR protein by interacting with its membrane-spanning domain 1 (MSD1) thus facilitating proper maturation and membrane localization In F508del-CFTR-expressing Fischer rat thyroid (FRT) cells VX-809 enhanced CFTR protein processing (EC50 0 1 M) and improved chloride transport (EC50 0 5 M) VX-809 is utilized predominantly as a research tool in CF studies to understand and restore CFTR function often in combination with CFTR potentiators
Medchemexpress LLC Cwi1-2 10 Mm - 1 Ml In Dmso | HY-153274-10MM-1ML DMSO
Cwi1-2 10 Mm - 1 Ml In Dmso